Title
Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention
Author
TNO Kwaliteit van Leven
Monraats, P.S.
Rana, J.S.
Nierman, M.C.
Pires, N.M.M.
Zwinderman, A.H.
Kastelein, J.J.P.
Kuivenhoven, J.A.
de Maat, M.P.M.
Rittersma, S.Z.H.
Schepers, A.
Doevendans, P.A.F.
de Winter, R.J.
Tio, R.A.
Frants, R.R.
Quax, P.H.A.
van der Laarse, A.
van der Wall, E.E.
Jukema, J.W.
Publication year
2005
Abstract
OBJECTIVES: We sought to identify polymorphisms in genes that predispose to restenosis. BACKGROUND: Variations in the lipoprotein lipase (LPL) gene have been implicated in a number of pathophysiologic conditions associated with coronary heart disease. The present study examines the impact of polymorphisms in the LPL gene on restenosis (defined by target vessel revascularization [TVR]) in a large patient population undergoing percutaneous coronary intervention (PCI). A mouse model for restenosis was used to further investigate LPL's role in restenosis. METHODS: The GENetic DEterminants of Restenosis (GENDER) project is a multicenter, prospective study design that enrolled 3,104 consecutive patients after successful PCI. These patients were genotyped for four different LPL gene polymorphisms. In apolipoprotein E (ApoE)*3-Leiden transgenic mice, arterial messenger ribonucleic acid (mRNA) was used to assess LPL expression during a cuff-induced restenotic process. RESULTS: Using multivariable analysis, carriers of the 447Ter allele of the LPL enzyme showed a lower risk of TVR compared with 447Ser homozygotes (p = 0.005). In the mouse model, LPL mRNA levels were increased 40-fold compared with control arteries at 6 h after cuff placement. CONCLUSIONS: The LPL C/G polymorphism (Ser447Ter), resulting in a truncation of the two C-terminal amino acids of the mature LPL protein, appears to be an important protective factor for TVR in humans. The role of LPL in this process was further established in a mouse model, where LPL expression was very strongly up-regulated in the target arterial wall, suggesting a contribution of this lipolytic enzyme to restenosis. Possibly, LPL Ser447Ter genotyping may lead to better risk stratification and tailored therapy in the prevention of restenosis after PCI. © 2005 by the American College of Cardiology Foundation. Chemicals / CAS: lipoprotein lipase, 83137-80-8, 9004-02-8; Lipoprotein Lipase, EC 3.1.1.34.
Subject
Biomedical Research
apolipoprotein E3
lipoprotein lipase
messenger RNA
adult
aged
allele
animal experiment
animal model
article
controlled study
coronary artery bypass graft
DNA polymorphism
female
follow up
gene expression
genetic association
genetic predisposition
genetic risk
genetic variability
genotype
heart muscle revascularization
heterozygote
homozygote
human
major clinical study
male
mouse
nonhuman
percutaneous coronary intervention
priority journal
restenosis
risk assessment
treatment outcome
Angioplasty, Transluminal, Percutaneous Coronary
Coronary Restenosis
Female
Humans
Lipoprotein Lipase
Male
Middle Aged
Polymorphism, Genetic
Risk Factors
To reference this document use:
http://resolver.tudelft.nl/uuid:6457a424-d2b3-48e8-a9d6-8d932527400a
DOI
https://doi.org/10.1016/j.jacc.2005.05.071
TNO identifier
238710
ISSN
0735-1097
Source
Journal of the American College of Cardiology, 46 (46), 1093-1100
Document type
article